Immunity June 2016 PMID 27332733

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Avery D Posey, Robert D Schwab, Alina C Boesteanu, Catharina Steentoft, Ulla Mandel, Boris Engels, Jennifer D Stone, Thomas D Madsen, Karin Schreiber, Kathleen M Haines, Alexandria P Cogdill, Taylor J Chen, Decheng Song, John Scholler, David M Kranz

Full text PDF Download social card

Mentions

Peak: 2 in Sep 2023

across 5 sources since Sep 2019

Extended reach

21,340

potential audience

Total likes

Video views

147

Mentions per month

Sep 2019 – Sep 2023

Where it's discussed

News20 articles
YouTube2 videos
Facebook2 posts
Reddit2 posts
X / Twitter1 posts

AI synopsis

What people are saying

Discussions reflect a positive outlook on the potential of targeting Tn-MUC1, with terms like 'promising' and 'exciting' used to describe the findings. Participants also demonstrate some depth by referencing how these targeted cells could overcome previous limitations in solid tumor treatments, emphasizing the study’s transformative implications.

AgreementModerate agreement

Most discussions support the idea that targeting specific antigens like Tn-MUC1 can advance cancer immunotherapy, indicating general agreement with the publication's findings.

InterestModerate interest

Participants show moderate interest, with some expressing curiosity about the clinical potential and wider applications of CAR T cell therapy.

EngagementModerate engagement

Comments include references to the research methods, such as how anti-Tn-MUC1 CAR T cells were tested, showing active engagement.

ImpactModerate impact

The discussions recognize the study's significance in opening new avenues for solid tumor treatment, suggesting a notable impact on future research and therapy development.

Abstract in brief

Genetically modified T cells, known as CAR T cells, show strong responses against certain targets in blood cancers, but their effectiveness in solid tumors is limited due to a lack of specific antigens.
Researchers identified that abnormal self-antigens, like the Tn glycoform of MUC1, can be effective targets for cancer treatment.
Anti-Tn-MUC1 CAR T cells effectively killed cancer cells and controlled tumor growth in models of T cell leukemia and pancreatic cancer, highlighting the potential of targeting unique antigens for therapy.

Read the full abstract

All mentions

Engineered CAR T Cells Targeting Tn Glycoform of MUC1 in Solid Tumors

Genetically engineered CAR T cells demonstrate promising responses against solid tumors by targeting the Tn glycoform of MUC1, a cancer-associated antigen. This approach shows potential for effective cancer treatment…

Informative · Sep 15, 2023 77 views

Targeting Tn-Glycoform of MUC1 with CAR T Cells for Cancer Therapy

GENETICALLY MODIFIED T CELLS, KNOWN AS CAR T CELLS, SHOW STRONG RESPONSES AGAINST BLOOD CANCERS, BUT THEIR EFFECTIVENESS IN SOLID TUMORS IS LIMITED DUE TO LACK OF SPECIFIC ANTIGENS. RESEARCHERS TARGETED THE Tn-Glycoform…

Informative · Sep 15, 2023 71 views

Matthew Sparks, MD

@Nephro_Sparks · X

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. #NephJC https://t.co/1IrWPlVCwL

Sep 3, 2019 · 21,194 followers View post →